Xtandi
Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer
Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)
Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer
Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations
Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer
TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.